gsk201303056k7.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending March 2013
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Notification of Transactions of Directors and Persons Discharging Managerial Responsibility
GlaxoSmithKline Performance Share Plan
Sale of shares to meet tax liabilities
The table below sets out changes in the interests of a Director and Persons Discharging Managerial Responsibility (PDMR) in the Ordinary Shares of GlaxoSmithKline plc arising from the sale of Ordinary Shares at a fair market value price of £14.55 per Ordinary Share on 1 March 2013 to meet tax liabilities following the vesting of awards granted under the GlaxoSmithKline 2009 Performance Share Plan (PSP).
| |
Number of Ordinary Shares sold to meet tax liabilities following the vesting of a
PSP award
|
|
Sir Andrew Witty*
|
63,152
|
|
Mr S Bicknell
|
6,973
|
|
Mr M Dunoyer
|
3,501
|
|
Mr A Hussain
|
2,789
|
|
Mr D Redfern
|
7,908
|
|
Ms C Thomas
|
12,139
|
* Denotes an Executive Director
The table below sets out changes in the interests of a Director and PDMRs in the American Depositary Shares (ADS) of GlaxoSmithKline plc arising from the withholding of ADS at a fair market value price of $44.03 per ADS on 1 March 2013 to meet tax liabilities following the vesting of awards granted under the PSP.
| |
Number of ADS withheld to meet tax liabilities following the vesting of a
PSP award
|
|
Dr M Slaoui*
|
17,232
|
|
Ms D Connelly
|
5,439
|
|
Mr W Louv
|
3,470
|
|
Mr D Troy
|
6,360
|
* Denotes an Executive Director
The Company, Directors and PDMRs were advised of these transactions on 4 March 2013.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
5 March 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: March 05, 2013
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc